Top

Published in:

01-10-2002 | Current Opinion

Does the Angiotensin II Receptor Antagonist Losartan Improve Cognitive Function?

Authors: Dr Michele A. Tedesco, Gennaro Ratti, Giovanni Di Salvo, Francesco Natale

Published in: Drugs & Aging | Issue 10/2002

Abstract

Newer classes of antihypertensive agents, such as angiotensin II receptor antagonists, may offer benefits to patients in addition to their ability to lower blood pressure. It is accepted that chronic hypertension contributes to the development of cerebrovascular and cardiovascular disease, and several studies have demonstrated a link between hypertension and reduced cognitive function, especially in patients not receiving antihypertensive medication. In an initial clinical trial, the angiotensin II receptor antagonist losartan was shown to improve cognitive function in patients with hypertension, including in those who were elderly (up to 73 years of age). This effect cannot be explained by a reduction in blood pressure alone and is likely to involve interactions with the diverse biological actions of the renin-angiotensin system.

Improving or maintaining cognitive function in patients with hypertension may translate into economic benefits beyond those expected due to blood pressure control, and would result in considerable quality-of-life benefits for the aging population.

Ferder L, Basso N, De Cacanagh EMV, et al. Aging, the renin system, and angiotensin II receptor antagonists. Cardiovasc Ther Today 2000; 7(3): 1–5

Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet 2000;355:637–45PubMedCrossRef

Ferder L, Inserra F, Romano L, et al. Enalapril ameliorates interstitial fibrosis in the aging kidney. J Am Soc Nephrol 1994; 5: 1147–52PubMed

Lever AF, Lyall P, Mortin I, et al. Angiotensin II, vascular structure and blood pressure. Kidney Int 1992; 41: 551–5

Haegarty AM. Functional and structural effects of ACE inhibitors on the cardiovascular system. Cardiology 1991; 79Suppl. 1: 3–9CrossRef

Tedesco MA, Ratti G, Aquino D, et al. Effects of losartan on hypertension and left ventricular mass: a long-term study. J Hum Hypertens 1998; 12: 505–10PubMedCrossRef

Wang DH, Prewitt RL. Captopril reduces aortic and microvascular growth in hypertensive and normotensive rats. Hyper-tension 1990; 15: 68–77

Tedesco MA, Ratti G, Mennella S, et al. Comparison of losartan and hydrochlorothiazide on cognitive function and quality of life in hypertensive patients. Am J Hypertens 1999; 12: 1130–4PubMedCrossRef

Cacciatore F, Abete P, Ferrara N, et al. The role of blood pressure in cognitive impairment in an elderly population: Os-servatorio Geriatrico Camapano Group. J Hypertens 1997; 15: 135–42PubMedCrossRef

10.

Tzourio C, Dufouil C, Ducimetière P, et al. Cognitive decline in individuals with high blood pressure. Neurology 1999; 53: 1948–52PubMedCrossRef

11.

Glynn RJ, Beckett LA, Hebert LE, et al. Current and remote blood pressure and cognitive decline. JAMA 1999; 281: 438–45PubMedCrossRef

12.

Skoog I, Lernfelt B, Landahl S, et al. A 15-year longitudinal study of blood pressure and dementia. Lancet 1996; 347: 1141–5PubMedCrossRef

13.

Kalmijn S, White L, Ross GW, et al. The metabolic cardiovascular syndrome and the risk of dementia in elderly men: the Honolulu-Asia Aging Study [abstract]. Neurology 2000; 54: A76

14.

Knopman DS, White L, Ross GW, et al. Cardiovascular risk factors and longitudinal cognitive changes in middle-aged adults [abstract]. Neurology 2000; 54: A230CrossRef

15.

The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145–53CrossRef

16.

Forette F, Seux ML, Staessen JA, et al. Prevention of dementia in the randomised double-blind placebo-controlled systolic hypertension in Europe (Syst-Eur) trial. Lancet 1998; 352: 1347–51PubMedCrossRef

17.

Starr JM, Whalley LJ, Deary IJ. The effects of antihypertensive treatment on cognitive function: results from the HOPE study. J Am Geriatr Soc 1996; 44: 411–5PubMed

18.

Blumenthal JA, Madden DJ, Pierce TW, et al. Hypertension affects neurobehavioural functioning. Psychosom Med 1993; 55: 44–50PubMed

19.

Breteler MM, van Swieten JC, Bots ML, et al. Cerebral white matter lesions, vascular risk factors, and cognitive function in a population-based study: the Rotterdam study. Neurology 1994; 44: 1246–52PubMedCrossRef

20.

Skoog I, Marcusson J, Blennow K. Dementia. It’s getting better all the time. Lancet 1998; 352Suppl. 4: 19–26

21.

Skoog I. Vascular aspects in Alzheimer’s disease. J Neural Transm Suppl 2000; 59: 37–43PubMed

22.

Strandgaard S, Paulson OB. Cerebrovascular consequences of hypertension. Lancet 1994; 344: 519–21PubMedCrossRef

23.

Prince M. Vascular risk factors and atherosclerosis as risk factors for cognitive decline and dementia. J Psychosom Res 1995; 39: 525–30PubMedCrossRef

24.

Heckbert SR, Longstreth WT, Psaty BM, et al. The association of antihypertensive agents with MRI white matter findings and with Modified Mini-Mental State Examination in older adults. J Am Geriatr Soc 1997; 45: 1423–33PubMed

25.

Kilander L, Nyman H, Boberg M, et al. Hypertension is related to cognitive impairment: a 20-year follow-up of 999 men. Hypertension 1998; 31:780–6PubMedCrossRef

26.

Guo Z, Fratiglioni L, Zhu L, et al. Occurrence and progression of dementia in a community population aged 75 years and older: relationship of antihypertensive medication use. Arch Neurol 1999; 56: 991–6PubMedCrossRef

27.

Richards SS, Emsley CL, Roberts J, et al. The association between vascular risk factor-mediating medications and cognition and dementia diagnosis in a community-based sample of African-Americans. J Am Geriatr Soc 2000; 48: 1035–41PubMed

28.

Wright JW, Harding JW. Brain angiotensin receptor subtypes AT1, AT2, and AT4 and their functions. Regul Pept 1995; 59: 269–95PubMedCrossRef

29.

Steckelings UM, Bottari SP, Unger T. Angiotensin receptor subtypes in the brain. Trends Pharmacol Sci 1992; 13: 365–8PubMedCrossRef

30.

Zhuo J, Moeller I, Jenkins, et al. Mapping tissue angiotensin-converting enzyme and angiotensin AT1, AT2, and AT4 receptors. J Hypertens 1998; 16: 2027–37PubMedCrossRef

31.

Li Z, Bains JS, Ferguson AV. Functional evidence that the angiotensin antagonist losartan crosses the blood-brain barrier in the rat. Brain Res Bull 1993; 30: 33–9PubMedCrossRef

32.

Polidori C, Ciccocioppo R, Nisato D, et al. Evaluation of the ability of losartan to cross the blood-brain barrier following acute intragastric treatment. Eur J Pharmacol 1998; 352: 15–21PubMedCrossRef

33.

Barnes NM, Champaneria S, Costall B, et al. Cognitive enhancing actions of DuP 753 detected in a mouse habituation paradigm. Neuroreport 1990; 1: 239–42PubMedCrossRef

34.

Jönsson L, Lindgren P, Wimo A, et al. Costs of mini mental state examination-related cognitive impairment. Pharmaco-economics 1999; 16: 409–16CrossRef

35.

Jönsson L, Gerth W, Fastbom J. The potential economic consequences of cognitive improvement with losartan. Blood Press 2002; 11: 46–52PubMedCrossRef

36.

Rizzo JA, Simons WR. Variations in compliance among hypertensive patients by drug class: implications for health care costs. Clin Ther 1997; 19: 1446–57PubMedCrossRef

37.

Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther 1998; 20: 1–10CrossRef

38.

Düsing R, Lottermoser K, Mengden T, et al. Compliance with antihypertensive therapy: comparison of losartan, amlodip-ine, and metoprolol [abstract]. Dtsch Med Wochenschr 2000; 125Suppl. 3: S50

39.

Moore MA, Edelman JM, Gadick LP, et al. Choice of initial antihypertensive medication may influence the extent to which patients stay on therapy: a community based study of a losartan-based regimen vs usual care. High Blood Press 1998; 7: 156–67

40.

Morrell RW, Park DC, Kidder DP, et al. Adherence to antihypertensive medications across the life span. Gerontologist 1997; 37: 609–19PubMedCrossRef

41.

Monane M, Bohn RL, Gurwitz JH, et al. The effects of initial drug choice and comorbidity on antihypertensive therapy compliance: results from a population-based study in the elderly. Am J Hypertens 1997; 10: 697–704PubMedCrossRef

42.

Lip GYH, Beever DG. A survey of the current practice of treating hypertension in primary care: the Rational Evaluation and ChoiceinHypertension(REACH)study. Drug Dev Clin Pract 1996; 8: 161–9

Title: Does the Angiotensin II Receptor Antagonist Losartan Improve Cognitive Function?
Authors: Dr Michele A. Tedesco
Gennaro Ratti
Giovanni Di Salvo
Francesco Natale
Publication date: 01-10-2002
Publisher: Springer International Publishing
Published in: Drugs & Aging / Issue 10/2002
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI: https://doi.org/10.2165/00002512-200219100-00001

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2002

Chronic Obstructive Pulmonary Disease

Sleep Disorders in Parkinson’s Disease

Anxiety Symptoms in Elderly Patients with Depression

Restless Legs Syndrome in the Older Adult

Ibutilide in Rapid Conversion of Atrial Flutter in Octogenarians

Health-Related Quality of Life and Long-Term Therapy with Pravastatin and Tocopherol (Vitamin E) in Older Adults

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials